NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has reported encouraging clinical data for its lead candidate NEO100, which could reshape the treatment landscape for recurrent brain cancer. According to an update from Stonegate Capital Partners, the Phase 2a trial met its primary endpoint, with a six-month progression-free survival (PFS) rate of 48.9% as measured by RANO 2.0 criteria, compared to a pre-specified benchmark of 20% (p=0.0047). The median overall survival (OS) reached 26.09 months, a figure that stands out against current salvage therapy outcomes of 6–9 months in this patient population.
The positive readout is seen as a critical step toward advancing NEO100 into a registrational program. The company intends to request a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss trial design, endpoints, and a potential approval pathway. This meeting is expected to be a key near-term catalyst, as regulatory alignment will determine the path to market for this investigational therapy.
Beyond the primary endpoint, the trial reported no major toxicities, suggesting a favorable tolerability profile that could support chronic, patient-friendly treatment. This is particularly important for a patient population that often faces debilitating side effects from existing therapies. The survival signal, however, is what analysts are emphasizing. “We view the survival signal as the more important read through,” noted Stonegate in their update, while cautioning that confirmation in a randomized study remains the next test.
NeOnc’s pipeline is also expanding beyond NEO100. The company has received regulatory clarity for its second asset, NEO212, including Phase 2 CMC clearance and FDA feedback indicating a potential accelerated approval pathway. This broadening of the investment case, with NEO100 also being explored in meningioma and pediatric brain tumors, adds long-term optionality, though funding will be crucial as development activities expand.
Financial results were secondary in the announcement, with research and development expenses increasing to $2.6 million from $0.7 million year-over-year, reflecting the heightened clinical activity. The company’s progress in both clinical and regulatory fronts suggests a maturing pipeline that could address significant unmet needs in brain cancer.
For more details, the full announcement can be viewed here. Stonegate Capital Partners provides investor relations and equity research services, and its affiliate, Stonegate Capital Markets, is a member of FINRA.
